title: Lack of Interactions Between an Antisense Oligonucleotide with 2'-O-(2-Methoxyethyl) Modifications and Major Drug Transporters.
abstract: ISIS 141923 is a model compound of 2'-O-(2-methoxyethyl) (2'-MOE) modified antisense oligonucleotides (ASOs). The purpose of this study is to determine whether ISIS 141923 is a substrate or an inhibitor against a panel of nine major uptake or efflux drug transporters, namely breast cancer resistance protein (BCRP), P-glycoprotein (P-gp), organic anion transporter (OAT)1, OAT3, organic cation transporter (OCT)1, OCT2, organic anion transporting polypeptide 1B (OATP1B)1, OATP1B3, and bile salt export pump (BSEP), in vitro. The uptake test system for transporters in the solute carrier (SLC) family (OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3) was studied in Madin-Darby canine kidney (MDCK)-II cells transfected to express the transporters of interest. BCRP was studied using carcinoma colon-2 (Caco-2) cells with endogenously expressed BCRP. P-gp transporter was studied in MDCK-multi-drug resistance 1 (MDR1) cells, while BSEP was studied using Spodoptera frugiperda 9 (Sf9) membrane vesicles containing human BSEP. The ISIS 141293 concentrations evaluated were 10 and 100 μM for the substrate and inhibition study, respectively. Cellular uptake of ISIS 141923 was analyzed using a high performance liquid chromatography-mass spectrometry method, while concentrations of known substrates (used as positive controls) of each transporters evaluated were determined by radiometric detection. At 10 μM ISIS 141923, there was no significant transporter-mediated uptake of ISIS 141923 (P > 0.05) in the SLC family, and the efflux ratios were not above 2.0 for either BCRP or P-gp. Therefore, no transporter-mediated uptake of ISIS 141923 was observed by any of the nine transporters studied. At 100 μM ISIS 141923, the % inhibition was in the range of -16.0% to 19.0% for the nine transporters evaluated. Therefore, ISIS 141923 is not considered as an inhibitor of the nine transporters studied. Overall, the results from this study suggest that it is unlikely that ISIS 141923 or similar 2'-MOE ASOs would interact with small molecule drugs either as a victim (substrate) or perpetrator (inhibitor) of major transporters in humans. The results from available clinical drug-drug interaction studies conducted with this class of compounds to date are also supportive of this conclusion.
authors.affiliation: 1 Ionis Pharmaceuticals, Inc. , Carlsbad, California.
authors.forename: Rosie Z
authors.initials: RZ
authors.lastname: Yu
authors.affiliation: 2 Optivia Biotechnology, Inc. , Menlo Park, California.
authors.forename: Mark S
authors.initials: MS
authors.lastname: Warren
authors.affiliation: 1 Ionis Pharmaceuticals, Inc. , Carlsbad, California.
authors.forename: Tanya
authors.initials: T
authors.lastname: Watanabe
authors.affiliation: 1 Ionis Pharmaceuticals, Inc. , Carlsbad, California.
authors.forename: Brandon
authors.initials: B
authors.lastname: Nichols
authors.affiliation: 2 Optivia Biotechnology, Inc. , Menlo Park, California.
authors.forename: Mirza
authors.initials: M
authors.lastname: Jahic
authors.affiliation: 2 Optivia Biotechnology, Inc. , Menlo Park, California.
authors.forename: Jane
authors.initials: J
authors.lastname: Huang
authors.affiliation: 1 Ionis Pharmaceuticals, Inc. , Carlsbad, California.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Burkey
authors.affiliation: 1 Ionis Pharmaceuticals, Inc. , Carlsbad, California.
authors.forename: Richard S
authors.initials: RS
authors.lastname: Geary
authors.affiliation: 1 Ionis Pharmaceuticals, Inc. , Carlsbad, California.
authors.forename: Scott P
authors.initials: SP
authors.lastname: Henry
authors.affiliation: 1 Ionis Pharmaceuticals, Inc. , Carlsbad, California.
authors.forename: Yanfeng
authors.initials: Y
authors.lastname: Wang
mesh_terms: D018435:ATP Binding Cassette Transporter, Subfamily B / Q000037:antagonists & inhibitors / Q000378:metabolism; D000074020:ATP Binding Cassette Transporter, Subfamily B, Member 11; D018528:ATP-Binding Cassette Transporters / Q000037:antagonists & inhibitors / Q000378:metabolism*; D000818:Animals; D001692:Biological Transport; D018938:Caco-2 Cells; D004285:Dogs; D004353:Drug Evaluation, Preclinical; D006801:Humans; D061985:Madin Darby Canine Kidney Cells; D009838:Oligodeoxyribonucleotides / Q000378:metabolism* / Q000494:pharmacology; D027361:Organic Anion Transporters / Q000037:antagonists & inhibitors / Q000378:metabolism*
chemical_list: C513055:ABCB1 protein, human; C093491:ABCB11 protein, human; D018435:ATP Binding Cassette Transporter, Subfamily B; D000074020:ATP Binding Cassette Transporter, Subfamily B, Member 11; D018528:ATP-Binding Cassette Transporters; C000613257:ISIS 141923; D009838:Oligodeoxyribonucleotides; D027361:Organic Anion Transporters